94% success breast cancer trial backs IceCure (ICCM) in new Dutch distribution push
Rhea-AI Filing Summary
IceCure Medical Ltd. (ICCM) reported entering an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology. Scovas will act as exclusive distributor for an initial term with a view to negotiating a longer-term agreement, subject to the parties’ agreement.
The Netherlands is highlighted as a strategic market, as the independent multicenter randomized THERMAC trial, conducted there, has advanced to Phase III with a focus on cryoablation. Previously published THERMAC data reported that ProSense® achieved a 94% success rate, a 0% complication rate, and 100% treatment tolerance without the need for general anesthesia among evaluated thermal ablation techniques.
Positive
- None.
Negative
- None.
Filing Explained
Beyond the distribution announcement, this Form 6-K states that the report is incorporated by reference into IceCure’s listed F-3 and S-8 registration statements, except for the third paragraph of the press-release exhibit, making the covered filing content part of those registration documents.
Key Figures
ProSense® success rate in THERMAC data: 94% success rate
ProSense® complication rate in THERMAC data: 0% complication rate
ProSense® treatment tolerance in THERMAC data: 100% treatment tolerance
3 metrics
ProSense® success rate in THERMAC data
94% success rate
Previously published THERMAC trial data for local treatment of early-stage breast cancer
ProSense® complication rate in THERMAC data
0% complication rate
Previously published THERMAC trial data for thermal ablation techniques
ProSense® treatment tolerance in THERMAC data
100% treatment tolerance
Previously published THERMAC trial data, without need for general anesthesia
Key Terms
cryoablation, thermal ablation, interventional oncology, treatment de-escalation, +1 more
5 terms
cryoablation medical
"developer of minimally-invasive cryoablation technology that destroys tumors by freezing"
A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.
thermal ablation medical
"evaluated thermal ablation as a potential treatment de-escalation approach"
Thermal ablation is a medical procedure that destroys unwanted tissue—most often tumors—by applying controlled heat through small needles or probes, rather than removing tissue with large incisions. For investors it signals demand for specialized devices, treatment centers and reimbursement changes because it offers a less invasive, often faster alternative to surgery—think of using a hot soldering iron to melt away a tiny damaged spot instead of tearing out a whole panel.
interventional oncology medical
"distribution of IceCure’s ProSense® cryoablation systems in the Netherlands for breast cancer and interventional oncology"
Interventional oncology is a branch of medicine that uses image-guided, minimally invasive procedures to treat cancer by targeting tumors directly—through techniques such as precise heat, cold, chemical delivery, or blocking a tumor's blood supply. Investors care because it drives demand for specialized devices, hospital services and repeatable outpatient procedures, and can change treatment costs and patient outcomes much like a targeted tool that removes a weed without digging up the whole garden.
treatment de-escalation medical
"evaluated thermal ablation as a potential treatment de-escalation approach for select patients"
Treatment de-escalation is the intentional lowering of the intensity, duration, or amount of a medical therapy while still aiming to keep the same health benefit; think of turning down the volume until you can still hear the song clearly. For investors, it matters because successful de-escalation can reduce drug or care costs, widen a therapy’s patient pool by making it safer or easier to use, and change future revenue forecasts and regulatory pathways for medical products.
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did IceCure Medical (ICCM) announce regarding distribution of ProSense® in the Netherlands?
IceCure Medical announced an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology. Scovas will serve as the exclusive distributor for an initial term with a view to a longer-term agreement.
Who is IceCure Medical’s (ICCM) partner in the new Netherlands agreement and what is its role?
The partner is Scovas Medical, an independent medical device distributor based in the Netherlands. Under the agreement, Scovas will be IceCure’s exclusive distributor for ProSense® in the Netherlands and will provide distribution and clinical sales support across relevant medical specialties.
What is the THERMAC trial mentioned by IceCure Medical (ICCM) and why is it important?
The THERMAC trial is an independent, multicenter randomized clinical trial in the Netherlands evaluating thermal ablation as a treatment de-escalation approach for select early-stage breast cancer patients. It has advanced to Phase III with a focus on cryoablation, creating clinical education and market-development opportunities for ProSense®.
What clinical results for ProSense® does IceCure Medical (ICCM) highlight from the THERMAC data?
Previously published THERMAC data reported that ProSense® cryoablation achieved a 94% success rate, a 0% complication rate, and 100% treatment tolerance without the need for general anesthesia, and that it had the highest complete ablation rate among the evaluated thermal ablation techniques.
How does IceCure Medical (ICCM) describe the potential benefits of minimally invasive cryoablation for breast cancer patients?
IceCure states that, for selected breast cancer patients, minimally invasive cryoablation may reduce the burden of surgery while supporting improved cosmetic outcomes, patient quality of life, and lower healthcare costs, and may support outpatient-friendly, image-guided oncology procedures.
What is IceCure Medical’s (ICCM) core business and flagship product?
IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems to destroy benign and cancerous tumors by freezing, focusing on breast, kidney, bone and lung cancer. Its flagship ProSense® system is marketed and sold worldwide for cleared and approved indications in the U.S., Europe and Asia.
AI-generated analysis. How Rhea-AI works. Not financial advice.
